

PRE-SCREENING INFORMATION FOR IL13RA2 CAR T CELL CLINICAL TRIAL

We are conducting a clinical trial of CAR T cells for patients with solid tumors. This CAR T cell targets a molecule called IL13Ra2 that is present on the surface of tumors of some patients. To determine if patients are eligible for this study, we are pre-screening samples from patients with solid tumors, with a focus on patients with:

- **Melanoma**
- **Neuroendocrine tumors, including paraganglioma and pheochromocytoma**
- **Adrenocortical Carcinoma**
- **Thyroid Carcinoma**
- **Sarcoma**
- **Other solid tumors**

Pre-screening involves the following steps:

- 1) Providing your consent by telephone with a member of the study team
- 2) The study team will request your tumor samples from the facility where your biopsy or surgery material is stored.
- 3) The study team will test your tissue for IL13Ra2 expression by IHC and report the results to you and your physician.

There is no commitment involved with pre-screening. If the test result is positive, you will be eligible to be screened for the clinical trial if this is something you wish to pursue in consultation with your oncologist. Below is some information about the clinical trial:

Study Name: Phase 1 Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T cells after a Nonmyeloablative Conditioning Regimen in Patients with Metastatic Melanoma and Other Solid Tumors.

Summary: This clinical trial investigates a novel gene therapy (IL13Ra2 CAR T cells) approach for advanced melanoma and other solid tumors. It aims to assess the safety and effectiveness of gene-modified immune cells targeting cancer cells.

Why is this study being done?: The trial seeks to determine the safety and potential effectiveness of IL13Ra2 CAR T cells in fighting cancer. By evaluating the dose and the cells' ability to attack cancer cells, researchers at UCLA, Stanford, and City of Hope aim to improve treatment options for advanced cancers.

Eligibility Criteria: Participants must have advanced melanoma or other solid tumors refractory to standard of care therapies. Further eligibility criteria will be discussed with the study doctor.

Contact Information: For more information or to discuss participation, please contact:

Christy Sidhu
(310) 206-5087

PICICenterResearch@Mednet.UCLA.edu